Engagement of chymase-positive mast cells in myocardial damage associated with COVID-19 - Scorecard - MDSpire

Engagement of chymase-positive mast cells in myocardial damage associated with COVID-19

  • By

  • Andrey V. Budnevsky

  • Sergey N. Avdeev

  • Ekaterina D. Arkhipova

  • Djuro Kosanovic

  • Viktoria V. Shishkina

  • Tatiana A. Chernik

  • Evgeniy S. Ovsyannikov

  • Inna M. Perveeva

  • Andrey A. Filin

  • Roman E. Tokmachev

  • Alexander V. Pertsev

  • Elena E. Ivanova

  • Tatiana V. Samoylenko

  • Lyubov N. Antakova

  • May 7, 2026

  • 0 min

Share

Clinical Scorecard: Involvement of Chymase-Positive Mast Cells in Cardiac Injury Linked to COVID-19

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with severe or critical COVID-19 who died from ARDS.
Care Setting

Key Highlights

  • Clarify the significance of the correlation between mast cells and myocardial injury indicators.

Guideline-Based Recommendations

Diagnosis

    Management

    • Utilize glucocorticosteroids and anticoagulants as primary treatments, specifying dosages.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Interleukin-6 inhibitors may be beneficial in severe cases with elevated inflammatory markers.

        Clinical Best Practices

        • Incorporate ongoing monitoring of mast cell activity post-treatment.

        Related Resources & Content

        Original Source(s)

        Engagement of chymase-positive mast cells in myocardial damage associated with COVID-19

        • by Andrey V. Budnevsky, Sergey N. Avdeev, Ekaterina D. Arkhipova, Djuro Kosanovic, Viktoria V. Shishkina, Tatiana A. Chernik, Evgeniy S. Ovsyannikov, Inna M. Perveeva, Andrey A. Filin, Roman E. Tokmachev, Alexander V. Pertsev, Elena E. Ivanova, Tatiana V. Samoylenko, Lyubov N. Antakova

        • May 7, 2026

        Related Content

        Respiratory viral infections today, heart failure tomorrow: implications for prevention

        MIS-C: Diagnosis, Management, and Outcomes

        Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age